Sirolimus-eluting coronary stent - REVA Medical

Drug Profile

Sirolimus-eluting coronary stent - REVA Medical

Alternative Names: Fantom; ReZolve; ReZolve Scaffold; ReZolve2

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator REVA Medical
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Coronary artery restenosis

Most Recent Events

  • 17 May 2016 Interim efficacy and adverse events data from the FANTOM II trial in Coronary artery restenosis released by REVA Medical
  • 15 Mar 2016 Biomarkers information updated
  • 10 Feb 2016 REVA Medical plans to file a CE Mark application for sirolimus-eluting coronary stent in the third quarter of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top